People with atrial fibrillation at intermediate risk of stroke benefit from oral anticoagulants, clinical trial finds — Live Feedhttps://www.live-feeds.com/feed/people-with-atrial-fibrillation-at-intermediate-risk-of-stroke-benefit-from-oral-anticoagulants-clinical-trial-findsContinuously updated, source-cited coverage. Oral Anticoagulants Benefit Atrial Fibrillation Patients at Intermediate Stroke Riskhttps://www.live-feeds.com/feed/people-with-atrial-fibrillation-at-intermediate-risk-of-stroke-benefit-from-oral-anticoagulants-clinical-trial-findshttps://www.live-feeds.com/feed/people-with-atrial-fibrillation-at-intermediate-risk-of-stroke-benefit-from-oral-anticoagulants-clinical-trial-finds#u52578Mon, 31 Aug 2026 00:47:36 +0000A clinical trial found that people with atrial fibrillation at intermediate risk of stroke benefit from oral anticoagulants, specifically direct oral anticoagulants (DOACs). The trial, SINGLE-AF, showed that DOACs cut clinical events in these patients. This finding supports the use of DOACs in this patient population.Why it mattersAtrial fibrillation is a common heart condition that increases the risk of stroke. Oral anticoagulants are often prescribed to patients at high risk of stroke, but the benefit for those at intermediate risk was unclear. The SINGLE-AF trial aimed to fill this knowledg